• Voting Rights and Shares Capital of the Company

    Source: Nasdaq GlobeNewswire / 11 Jan 2023 16:15:00   America/New_York

    In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)

    PARIS, Jan. 11, 2023 (GLOBE NEWSWIRE) --

    Market: Euronext Paris / Nasdaq
    Euronext Compartment: B
    ISIN code: FR0011341205
    Nasdaq: NBTX
    Bloomberg: NANO:FP
    Reuters: NANO.PA
    Website: www.nanobiotix.com

    Date
    		Number of Shares Outstanding

    		Total number of voting rights
    Total voting rights, theoretical1
    		Total voting rights, exercisable2
    December 31, 2022
    		34,875,87236,287,44936,265,331

    As a reminder, Nanobiotix has announced on December 21, 2022, that it has ended the liquidity contract signed on October 23, 2012, with Gilbert Dupont. The termination is effective from December 20, 2022, after the close of Euronext market.

    According to the article L.233-8 II of the French Commercial Code, Nanobiotix will make a new monthly publication of the total number of voting rights and shares comprising Nanobiotix’s capital if those figures differ from the information previously disclosed.

    About NANOBIOTIX

    Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The company is leveraging its proprietary nanoparticle platform, including its lead product candidate, radiotherapy activated NBTXR3, to develop a pipeline of therapeutic options designed to enhance local and systemic control of solid tumors with an initial focus on the treatment of head and neck cancers. 

    For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.

    ____________________________

    1 The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

    2 The total number of exercisable at a Shareholders’ Meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed, in accordance with the AMF recommendation of July 17, 2007.

    Contacts

    Nanobiotix

    Nanobiotix Communications
    Brandon Owens
    VP, Communications
    +1 (617) 852-4835
    contact@nanobiotix.com


    Nanobiotix Investor Relations
    Kate McNeil
    SVP, Investor Relations
    +1 (609) 678-7388
    investors@nanobiotix.com

    Media Relations

    France –     Ulysse Communication
    Pierre-Louis Germain
    + 33 (0) 6 64 79 97 51
    plgermain@ulysse-communication.com


    US - LifeSci Advisors 
    Ligia Vela-Reid 
    +44 (0) 7413825310 
    lvela-reid@lifesciadvisors.com

    Attachment


Share on,